Dry Powder Inhalers (DPIs)

Dry Powder Inhalers (DPIs) are a widely used and increasingly important delivery system for respiratory medications, particularly in the treatment of asthma, chronic obstructive pulmonary disease (COPD), and other pulmonary conditions. As an alternative to metered-dose inhalers (MDIs) and nebulizers, DPIs offer several advantages in terms of convenience, environmental impact, and patient compliance.

Advantages of Bona's DPIs

One of the key benefits of DPIs is that they are breath-actuated. Unlike MDIs, which require hand-breath coordination, DPIs rely on the patient’s own inhalation to disperse the drug in the form of fine powders. This feature reduces the risk of incorrect usage and improves drug delivery efficiency.

"Visitors to booth #8.0M30 at CPHI Worldwide taking place in Frankfurt, Germany in October are invited to visit our stand and learn more about our DPIs."

In addition, DPIs eliminate the need for propellants, such as hydrofluoroalkanes (HFAs), making them more environmentally friendly and compliant with global regulations aimed at reducing greenhouse gas emissions. The solid powder formulation also enhances the chemical stability of many active pharmaceutical ingredients, extending product shelf life and reducing the need for cold-chain storage.

For patients, DPIs are typically compact, portable, and easy to carry, enabling on-the-go therapy. The absence of propellant spray sensation also makes them more comfortable to use, especially for long-term treatment.

Bona Pharma has been actively engaged in research and development of DPI devices. We collaborate closely with formulation scientists and engineers to ensure that our inhalation devices achieve high fine particle fractions, consistent dosing, and user-friendly ergonomics.

Features of Bona's DPIs

1. Applicable to capsule 3#;
2. Application: COPD and Asthma treatment medicines;
3. Single-dose;
4. ISO13485 Certified, with CE;
5. Materials comply with CP, EP, USP, food and drug contact requirements;
6. Custom design and development are available.

Furthermore, Bona Pharma is equipped with professional testing equipment to fulfill the customized requirements of customers regarding airflow resistance.

Bona remains committed to advancing DPI technology through continuous research, device optimization, and product diversification.

By combining high-performance inhalers with tailored formulation solutions, we aim to provide patients worldwide with more effective, sustainable, and convenient respiratory therapy options.

We sincerely welcome all of you to explore more possibilities with our company to achieve win-win cooperation and learn more about our DPIs and other healthcare packaging solutions.